CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded to other treatments. But until now, the underlying biological pathways enabling anti-cancer responses have not been thoroughly examined. Understanding these pathways is important for designing future generations of CAR T-cell therapies, including reducing side effects, preventing […]

Continue reading »